IRLAB Therapeutics ABOSTO:IRLAB A -1.83%36 PB Ratio is 2.81 as of Jul. 06, 2026, which is 53% below its 10-year median of 6.02. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 36/100 and a GF Value™ of kr11.75 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,230 Biotechnology companies, IRLAB Therapeutics AB ranks better than 52.03% on this metric.
IRLAB Therapeutics AB stock PB Ratio (=2.81) is close to 2-year low of 2.61.
The historical rank and industry rank for IRLAB Therapeutics AB's PB Ratio or its related term are showing as below:
OSTO:IRLAB A'
s PB Ratio Range Over the Past 10 Years
Min: 1.56 Med: 6.02 Max: 82.03
Current: 2.81
During the past 13 years, IRLAB Therapeutics AB's highest PB Ratio was 82.03. The lowest was 1.56. And the median was 6.02.
OSTO:IRLAB A's PB Ratio is ranked better than 52.03% of 1230
companies
in the Biotechnology industry
Industry Median: 2.99
vs OSTO:IRLAB A: 2.81
During the past 12 months, IRLAB Therapeutics AB's average Book Value Per Share Growth Rate was 453.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -59.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -48.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -16.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of IRLAB Therapeutics AB was 60.80% per year. The lowest was -59.10% per year. And the median was 11.85% per year.
Back to Basics: PB Ratio
IRLAB Therapeutics AB (OSTO:IRLAB A) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IRLAB A vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
IRLAB Therapeutics AB (OSTO:IRLAB A) has a PB Ratio of 2.81 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IRLAB Therapeutics AB and its competitors. This is 53% below median its historical median of 6.02. Over the past decade, IRLAB Therapeutics AB's PB Ratio has ranged from 1.56 to 82.03. According to the industry distribution chart, IRLAB Therapeutics AB ranks #590 out of 1230 companies in the Biotechnology industry, placing it in the top 48%.
Is IRLAB Therapeutics AB's PB Ratio too high?
IRLAB Therapeutics AB's current PB Ratio of 2.81 is 53% below median its 10-year median of 6.02. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 82.03. The Biotechnology industry median PB Ratio is 2.99. IRLAB Therapeutics AB's value of 2.81 is 6% below this industry median. Based on the distribution chart, IRLAB Therapeutics AB ranks #590 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #590 out of 1230 companies for PB Ratio. This puts IRLAB Therapeutics AB in the upper half of its industry. The industry median PB Ratio is 2.99. IRLAB Therapeutics AB's value of 2.81 is 6% below this benchmark. Historically, IRLAB Therapeutics AB's own PB Ratio has ranged from 1.56 to 82.03 over the past decade. While the company's 10-year median is 6.02 vs. the industry median of 2.99, IRLAB Therapeutics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IRLAB Therapeutics AB's current PB Ratio of 2.81 is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current PB Ratio is 2.81, which is 53% below median its own 10-year median of 6.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.75, compared to a current price of kr1.29 — trading 89% below its estimated fair value. The current PB Ratio is 2.81, which is 53% below median its 10-year median of 6.02 and 6% below the Biotechnology industry median of 2.99. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current PB Ratio is 2.81 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.29 is trading 89% below its estimated GF Value™ of kr11.75.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
PB Ratio: 2.81 (53% below median its 10-year median of 6.02)
GF Value™: kr11.75 vs. price of kr1.29 (89% below fair value)
Industry Position: 6% below the Biotechnology median (#590 of 1230)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score
Get the complete analysis for OSTO:IRLAB A
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
